Octaphlorethol A, a marine algae product, exhibits antidiabetic effects in type 2 diabetic mice by activating AMP-activated protein kinase and upregulating the expression of glucose transporter 4
- Authors
- Lee, Seung-Hong; Ko, Seok-Chun; Kang, Min-Cheol; Lee, Dae Ho; Jeon, You-Jin
- Issue Date
- May-2016
- Publisher
- PERGAMON-ELSEVIER SCIENCE LTD
- Keywords
- Octaphlorethol A; Type 2 diabetes; AMP-activated protein kinase; Glucose transporter 4; Phosphoenolpyruvate carboxykinase; Glucose-6-phosphatase
- Citation
- FOOD AND CHEMICAL TOXICOLOGY, v.91, pp.58 - 64
- Journal Title
- FOOD AND CHEMICAL TOXICOLOGY
- Volume
- 91
- Start Page
- 58
- End Page
- 64
- URI
- https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/8338
- DOI
- 10.1016/j.fct.2016.02.022
- ISSN
- 0278-6915
- Abstract
- Octaphlorethol A (OPA), a type of phlorotannin isolated from Ishige foliacea has been shown to have antidiabetic activities. However, the mechanism of action of OPA in type 2 diabetes has not been investigated extensively. Here, we investigated the antidiabetic effects and mechanism of OPA in C57BL/KsJ-db/db mice, a model of type 2 diabetes. Levels of postprandial blood glucose were significantly lower in OPAtreated db/db mice than in control db/db mice. In addition, the OPA supplements significantly improved fasting blood glucose level and impaired glucose tolerance compared to control db/db mice. OPA also significantly decreased the level of serum insulin, augmented the activation of AMP-activated protein kinase (AMPK), and increased the expression of glucose transporter 4 (GLUT4) protein in skeletal muscle. In addition, it significantly suppressed the increases in hepatic mRNA expression level of phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-phosphatase (G6Pase), gluconeogenesis-related enzymes. Therefore, the mechanisms of OPA may involve suppression of gluconeogenesis by inhibiting PEPCK and G6Pase activity in the liver and affecting GLUT4-mediated glucose uptake in skeletal muscle through activation of AMPK. These findings provide a new insight into the antidiabetic clinical applications of OPA and demonstrate the potential of OPA as a new drug candidate for type 2 diabetes. (C) 2016 Elsevier Ltd. All rights reserved.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - 의과대학 > 의학과 > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/8338)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.